Stifel Nicolaus Issues Pessimistic Forecast for X4 Pharmaceuticals (NASDAQ:XFOR) Stock Price

X4 Pharmaceuticals (NASDAQ:XFOR) had its target price dropped by Stifel Nicolaus from $5.00 to $4.00 in a report released on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock.

X4 Pharmaceuticals Stock Performance

Shares of XFOR opened at $0.28 on Thursday. The firm has a market capitalization of $46.73 million, a P/E ratio of 3.47 and a beta of 0.39. The company has a debt-to-equity ratio of 0.79, a current ratio of 6.07 and a quick ratio of 6.04. X4 Pharmaceuticals has a one year low of $0.26 and a one year high of $1.60. The business has a fifty day moving average of $0.60 and a 200 day moving average of $0.76.

X4 Pharmaceuticals (NASDAQ:XFOR) last announced its earnings results on Wednesday, August 14th. The company reported $0.01 earnings per share (EPS) for the quarter. The firm had revenue of $3.43 million during the quarter. As a group, sell-side analysts anticipate that X4 Pharmaceuticals will post -0.65 EPS for the current year.

Insider Buying and Selling

In other news, COO Mary Dibiase sold 67,695 shares of X4 Pharmaceuticals stock in a transaction on Monday, October 7th. The shares were sold at an average price of $0.57, for a total transaction of $38,586.15. Following the transaction, the chief operating officer now owns 452,060 shares in the company, valued at $257,674.20. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, CEO Paula Ragan sold 239,436 shares of the business’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $0.55, for a total value of $131,689.80. Following the transaction, the chief executive officer now directly owns 1,057,713 shares in the company, valued at $581,742.15. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Mary Dibiase sold 67,695 shares of the stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $0.57, for a total value of $38,586.15. Following the sale, the chief operating officer now owns 452,060 shares of the company’s stock, valued at $257,674.20. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 580,800 shares of company stock valued at $321,447. 1.62% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD raised its position in shares of X4 Pharmaceuticals by 46.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 39,307 shares of the company’s stock valued at $55,000 after buying an additional 12,514 shares during the last quarter. Rhumbline Advisers grew its stake in X4 Pharmaceuticals by 14.6% during the second quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock valued at $109,000 after acquiring an additional 23,831 shares in the last quarter. SG Americas Securities LLC purchased a new position in X4 Pharmaceuticals during the third quarter valued at $37,000. Ensign Peak Advisors Inc increased its holdings in X4 Pharmaceuticals by 4.6% in the 2nd quarter. Ensign Peak Advisors Inc now owns 2,546,458 shares of the company’s stock valued at $1,477,000 after acquiring an additional 111,032 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in X4 Pharmaceuticals in the 2nd quarter worth $65,000. 72.03% of the stock is owned by hedge funds and other institutional investors.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.